Conference Coverage

VIDEO: Researchers closing in on the elusive ‘male pill’


 

REPORTING FROM ENDO 2018

Dimethandrolone, a modified form of testosterone, just might turn out to be the long-sought male contraceptive pill.

It blocks gonadotropin signaling and testosterone production in the testes. When capsules ranging in dose from 100 mg to 400 mg were given once daily to 100 men in a randomized, placebo controlled trial, the drop in testosterone was more than sufficient to block sperm production. Testosterone levels jumped back up to normal after the end of the 28-day trial, all without inducing liver toxicity or other serious problems.

“We are very excited [about] the results. It’s a big step forward in the development of the male pill. Our last great advance in male contraception was over 300 years ago with the development of the condom,” said senior investigator Stephanie Page, MD, PhD, head of the division of metabolism, endocrinology, and nutrition at the University of Washington, Seattle.

Pages

Recommended Reading

Testosterone: Moderate sexual, mood benefits; no vitality benefit
MDedge Cardiology
Drug interaction myths
MDedge Cardiology
VIDEO: Telecardiology improves chronic care management, reduces cost
MDedge Cardiology
AAA screening showed no mortality reduction in new trial
MDedge Cardiology
New PAD guidelines expected to boost awareness and treatment
MDedge Cardiology
The Barbershop Study: Hypertension causes nocturia
MDedge Cardiology
Clinicians underusing statins, aspirin in HIV patients
MDedge Cardiology
Testosterone Trials’ cardiac, cognitive results disappoint
MDedge Cardiology
Alpha-blockers deemed safe in heart failure
MDedge Cardiology
Nocturia linked to hypertension, diuretic use in community-based study of black men
MDedge Cardiology